Selected Recent Publications and Invited Papers:

....................................

R. B. Holtz, Ph.D.

R. B. Holtz, Cancer Vaccines: Strategic Planning of Manufacturing Development. Invited speaker. 14th Internation Conference on Gene Therapy, September, 2006, Dallas

R. B. Holtz, Mulitsite Collaborations for the Institutional Sponsor, Invited Speaker, Navigating Through the Sponsor-Investigator IND Minefield Conference, University of Arkansas for Medical Sciences, April, 2007, Little Rock.

R. B. Holtz, Validating Vaccine Facilities : Focus on Early Stage Companies and Institutions. Cambridge Healthcare Institute Conference, Immunotherapeutics & Vaccines Summitt. August, 2007,Boston

R. B. Holtz, Manufacturing Patient Specific Therapies: Strategic, Regulatory, and Scale-up Issues. Cell and Tissue Bioprocessing Meeting, October, 2007 Austin, TX

McCormick, A.A., Reddy, S., Reinl, S.J., Cameron, T.I., Czerwinkski, D.K., Vojdani, F., Hanley, K., Garger, S.J., White,E.L., Novak, J., Barrett, J., Holtz, R.B., Tusé, D., and Levy, R. Plant- produced Idiotype Vaccines for the Treatment of Non-Hodgkin’s Lymphoma: Safety and Immunogenicity in a Phase I Clinical Study. PNAS, Vol. 105, 10131 -10136, 2008

R. B. Holtz, An Aggressive Facilities and Quality Systems Approach for Developing Biopharmaceutical Manufacturers. Cambridge Healthcare Institute Protein Conference, San Diego CA, January, 2008

R. B. Holtz, Phillip B. Maples, Biaoru Li, Courtney Haddock, Eli Gutierrez, Padmsini Kumar, Lori Debetaz, Neil Senzer, JohnNemunaitis. Integration of LC Maldi-TOF/TOF Mass Spectrometry to Provide Proteogenomic Information for the Manufacture of Patient Specific Cancer Therapies. American Society for Gene Therapy, Boston, 2008

....................................

S. Micheal Owens, Ph.D.
W. Brooks Gentry , MD

Kumar P, Gentry WB, Arora H. Ultrasound Guidance in Regional Anesthesia, J Anaesth Clin Pharmacol 2007;23(2):121-8

Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis) but not kava kava (Piper methysticum) inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008; 83(1): 61-69

Gentry WB, Rüedi-Bettschen D, Owens SM. Development of Active and Passive Human Vaccines to Treat Methamphetamine Addiction. Human Vaccines 2009 5(4):1-8.

McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, and Oliveto A. Open Label Pilot Study of Modafinil for Methamphetamine Dependence. Journal of Clinical Psychopharmacology 2009;29(5):488-91.

White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, and Owens SM. Vulnerability to (+)-Methamphetamine Effects and the Relationship to Drug Disposition in Pregnant Rats during Chronic Infusion. Toxicological Sciences 2009;111(1):27-36.

Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EP, Gentry WB, West M, Che Y, Carroll FI, and Owens SM. Functional and Biological Determinants Affecting the Duration of Action and Efficacy of Anti-(+)-methamphetamine Monoclonal Antibodies in Rats. Vaccine 2009 in press

....................................

W. Brooks Gentry , MD

6/29/06 - Central AR District, AR Dental Society, Little Rock, AR: “Meth Mouth and Other Maladies.”

2/13/07 - University of Arkansas, Fayetteville, Upper Level Medications Development Seminar. “Endpoints in Clinical Testing and Human Trials”

2/19/08 - University of Arkansas, Fayetteville, Upper Level Medications Development Seminar. “Endpoints in Clinical Testing and Human Trials”

1/7/09 - West Little Rock Rotary Club, Little Rock, AR. “New Medications for Drug Abuse.”

Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis) but not kava kava (Piper methysticum) inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008; 83(1): 61-69

Gentry WB, Rüedi-Bettschen D, Owens SM. Development of Active and Passive Human Vaccines to Treat Methamphetamine Addiction. Human Vaccines 2009 5(4):1-8.

McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, and Oliveto A. Open Label Pilot Study of Modafinil for Methamphetamine Dependence. Journal of Clinical Psychopharmacology 2009;29(5):488-91.

White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, and Owens SM. Vulnerability to (+)-Methamphetamine Effects and the Relationship to Drug Disposition in Pregnant Rats during Chronic Infusion. Toxicological Sciences 2009;111(1):27-36.

Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EP, Gentry WB, West M, Che Y, Carroll FI, and Owens SM. Functional and Biological Determinants Affecting the Duration of Action and Efficacy of Anti-(+)-methamphetamine Monoclonal Antibodies in Rats. Vaccine 2009 in press

....................................

Ralph Henry, Ph.D.

Marty, NJ, R Dakshinamurthy, AD Kight, NE Lewis, D Fologea, TKS Kumar, RL Henry, RL Goforth (2009). The membrane-binding motif of chloroplast signal recognition particle receptor (cpFtsY) regulates GTPase activity. J. Biol. Chem 284(22), 14891-14903

Ananthamurthy, K, KM Kathir, A Kight, RL Goforth, RL Henry, TKS Kumar (2008). 1H, 13C and 15N Resonance Assignments of the C-terminal Chromo domain of the chloroplast signal recognition particle. J Biomolecular NMR Assignments 2(1):37-39.

KM Kathir, D Rajalingam, V Sivaraja, A Kight, RL Goforth, C Yu, RL Henry, TKS Kumar (2008). Assembly of Chloroplast Signal Recognition Particle involves Structural Rearrangement in cpSRP43 J Mol Biol 381(1):49-60

Lewis, P, I Fritch, RE Gawley, RL Henry, A Kight, JO Lay, R Liyanage, J McLachlin (2008). Dynamics of saxitoxin binding to saxiphilin c-lobe reveals conformational change. Toxicon. 51:208-217.

Henry, RL, RL Goforth, D Scheunemann (2007). Chloroplast SRP/FtsY and Alb3 in Protein Integration into the Thylakoid Membrane; In The Enzymes (Volume 25; Molecular Machines Involved In Protein Transport Across Cellular Membranes), Ross E. Dalbey, Carla Koehler, and Fuyuhiko Tamanoi Editors.

....................................

Misty Ward Stevens, Ph.D.
Publications (note former name was M. Moore)

Cai Y, Moore M, Goforth R, Henry R, Beitle R (2004) Genomic data for alternate production strategies. I. Identification of major contaminating species for Cobalt(+2) immobilized metal affinity chromatography. Biotechnol Bioeng. 88(1):77-83.

Goforth RL, Peterson EC, Yuan J, Moore MJ, Kight AD, Lohse MB, Sakon J, Henry RL. (2004) Regulation of the GTPase cycle in post-translational signal recognition particle-based protein targeting involves cpSRP43. J Biol. Chem. 279(41):43077-84.

Moore M, Goforth RL, Mori H, Henry R. (2003) Functional interaction of chloroplast SRP/FtsY with the ALB3 translocase in thylakoids: substrate not required. J Cell Biol. 162(7):1245-54.

Yuan, J, A Kight, R Goforth, M Moore, EC Peterson, J Sakon, R Henry. (2002) ATP stimulates SRP/FtsY-supported protein integration in chloroplasts. J Biol. Chem. 277(35):32400-4.

Jiang, F, L Yi, M Moore, M Chen, T Rohl, KJ van Wijk, JW de Gier, R Henry, R Dalbey. (2002) Chloroplast YidC homologue Albino3 can functionally complement the bacterial YidC depletion strain and promote membrane insertion of both bacterial and chloroplast thylakoid proteins. J Biol. Chem. 277(22):19281-8.

Mant, A, CA Woolhead, M Moore, R Henry, C Robinson. (2001) Insertion of PsaK into the thylakoid membrane in a 'horse-shoe' conformation occurs in the absence of signal recognition particle, nucleoside triphosphates or functional Albino3. J Biol. Chem. 276(39):36200-6.

Woolhead, CA, S Thompson, M Moore, C Tissier, A Mant, A Rodger, R Henry, C Robinson. (2001) Distinct Albino3-dependent and -independent pathways for thylakoid membrane protein insertion. J Biol. Chem. 276(44):40841-6.

Moore, M, MS Harrison, EC Peterson, R Henry. (2000) Chloroplast Oxa1p homolog, Albino3, functions in post-translational integration of the light harvesting chlorophyll-binding protein into thylakoid membranes. J Biol. Chem. 275(3):1529-32.

....................................
top of page